This new biomarker was discovered using Compugen's GeneVa platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.

Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90 percent of whom are affected by type 2 diabetes. During the past few years, extensive efforts by others searching for genetic markers for type 2 diabetes have utilized numerous genome-wide association studies, involving thousands of patients globally. Several validated genetic markers have been found; however, combining all the discovered biomarkers still explains only a small fraction of the heritability of the disease, so the need for additional markers continues to exist.

From the approximately 350,000 multiple nucleotide genetic variations predicted by the GeneVa platform, a very small set of variations was selected as being potentially related to type 2 diabetes in Caucasians. This very small set, consisting of only 135 variations, was then tested in a genotyping experiment. In this study, CGEN-40001, a novel 15bp insertion in PFKP (a key regulatory enzyme in glycolysis), demonstrated the predicted correlation with type 2 diabetes in Caucasians. This correlation was then validated in a second study based on an independent set of samples. According to the two studies performed by Compugen, approximately 15 percent of the Caucasian population has at least one copy of this insertion. Furthermore, the studies showed that the presence of this insertion increases the risk of type 2 diabetes by 50-80 percent.

About Type 2 Diabetes

Diabetes mellitus type 2 is a chronic, life-long disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. When glucose builds up in the blood rather than being absorbed into cells, it can lead to diabetic complications. Over time, diabetes can lead to blindness, kidney failure and nerve damage. Diabetes is also an important factor in accelerating the hardening and narrowing of arteries (atherosclerosis), which generally leads to strokes, coronary heart disease and other large blood vessel diseases. If left uncontrolled, the consequences can be life-threatening. However, type 2 diabetes is manageable and can be prevented. "First-line" treatment consists of diet, weight control and physical activity.

At present, an estimated 8 percent of the U.S. population suffers from diabetes, 90 percent of whom are affected by type 2 diabetes. Moreover, prevalence rates in the U.S. have more than doubled since 1990, leading the U.S. Center for Disease Control to characterize this continuing increase as an epidemic. Worldwide, more than 150 million people are estimated to have this disorder; this number is expected to double by 2025.

Compugen's GeneVa platform incorporates an in silico database of approximately 350,000 predicted human genetic variations. Each of these predicted variations consists of multiple consecutive nucleotides (in general varying between 2 and 500 nucleotides) and can be in the form of insertions, deletions and/or copy-number variations in the genome. Thus, these GeneVa variations are much larger than the more commonly known SNP's (Single Nucleotide Polymorphisms), millions of which are known to occur in the human genome, and with each SNP involving a change in only one nucleotide. It is generally believed that larger variations should have a more significant impact.

GeneVa utilizes special purpose algorithms and other computational biology tools to select from the large database of genetic variations those variations that are predicted to be associated with the specific clinical phenotypes of interest, such as response or non-response to a specified drug of interest, or predisposition to a specified disease. Another key feature of the platform is a proprietary genotyping capability that allows the testing of multiple genetic variations on hundreds of DNA samples in a precise and cost-effective manner.

Compugen is a drug and diagnostic product candidate discovery company.

((Comments on this story may be sent to health@closeupmedia.com))

Compugen Ltd. (NASDAQ: CGEN)

Compugen Ltd. (NASDAQ: CGEN) closed Friday up 1.25% on 52,900 shares traded.

To view the complete release, please visit: http://wallstreetnewsalert.com/fullstory.php?id=1706

November 9, 2009 - Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen's GeneVa platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.

Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90% of whom are affected by type 2 diabetes. During the past few years, extensive efforts by others searching for genetic markers for type 2 diabetes have utilized numerous genome-wide association studies, involving thousands of patients globally. Several validated genetic markers have been found; however, combining all the discovered biomarkers still explains only a small fraction of the heritability of the disease, so the need for additional markers continues to exist.

About the company:

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's current collaborations include Bayer Schering Pharma, Biosite, Medarex, Inc., Merck & Co., Inc., Merck Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd. www.evogene.com (TASE: EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate Web site at www.cgen.com.

East West Bancorp, Inc. (NASDAQ: EWBC)

East West Bancorp, Inc. (NASDAQ: EWBC) closed Friday up 3.10% on over 1.8 million shares traded.

To view the complete release, please visit: http://wallstreetnewsalert.com/fullstory.php?id=1708

November 6, 2009 - East West Bancorp, Inc. (NASDAQ: EWBC), parent company of East West Bank, announced today that it has acquired the banking operations of San Francisco, California based United Commercial Bank (UCB) in a Federal Deposit Insurance Corporation (FDIC) assisted transaction. Under the terms of the transaction, East West will receive $10.4 billion in assets, including $7.7 billion in loans, and assume $9.2 billion in liabilities, including $6.5 billion in deposits of UCB. The FDIC and East West have entered into a loss sharing agreement covering substantially all acquired loans.

This strategically compelling and financially attractive transaction creates the second largest independent bank headquartered in California and the largest bank in the nation focused on serving the Asian American community. East West Bank, now over $19 billion in assets, operates 137 branches worldwide, including 112 branches in California and 21 branches in key markets across the country, including New York, Atlanta, Boston, Houston, and Seattle. East West operates four full-service branches in Greater China, including two branches in Hong Kong, and branches in Shanghai and Shantou. The bank also has representative offices in Beijing, Guangzhou, Shanghai and Shenzhen, China, and Taipei, Taiwan. The Shanghai, China, subsidiary of United Commercial (UCB-China), was also part of today's transaction. The agreement between the FDIC and East West Bank will not affect the normal business operation of UCB-China. East West Bank will extend support to UCB-China where necessary.

About the company:

East West Bancorp is a publicly owned company with over $19 billion in assets. The Company's wholly owned subsidiary, FDIC-insured East West Bank, is the second largest bank headquartered in California and the largest bank in the nation focused on serving the Asian American community. East West Bank has 137 branches, including 112 branches in California, nine branches in New York, five branches in metropolitan Atlanta, three branches in Massachusetts, two branches in Houston, and two branches in Seattle. East West Bank has four full-service branches in Greater China, including two branches in Hong Kong, one branch in Shanghai, and one branch in Shantou. The Bank also has representative offices in Beijing, Guangzhou, Shanghai and Shenzhen, China, and Taipei, Taiwan.

Receive our free mobile stock alerts formatted especially for your cell phone by texting the word "press" in the subject line to 68494.

*** This free service can be discontinued at any time by replying to any one of the alerts with the word "stop".

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 200 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button.

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its' Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks

WSCF has not been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. However, WSCF may receive compensation for future services. Any additional compensation will be disclosed at such time that WSCF is aware of a clients desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

CONTACT: Wall Street News Alert e-mail: info@wallstreetnewsalert.com WWW: http://www.wallstreetnewsalert.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Following its in silico prediction and selection, CGEN-226 was validated experimentally, and patent applications covering this splice variant were made for various diagnostic and therapeutic applications, the company said.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

(NASDAQ: BCSI - Blue Coat Systems, Inc.)

(NASDAQ: BJRI - BJ's Restaurants, Inc.)

(NASDAQ : BRKR - Bruker Corp.)

(NASDAQ: CBST - Cubist Pharmaceuticals, Inc.)

(NASDAQ: CGEN - Compugen Ltd.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: GSAE - Green Star Alternative Energy, Inc.)

LATEST NEWS!!

Green Star Erects Wind Sensor at Ram

SAN DIEGO, Nov 09, 2009 -- Green Star Alternative Energy, Inc. (Pink Sheets: GSAE) ("GSAE" or the "Company") (http://www.greenstarae.com) is pleased to announce the installation of a wind measurement tower just outside the settlement of Ram, located in the 50 MW region of Veliko Gradiste.

The terrain had been carefully analysed and months of preparation and licensing have culminated in this deployment. The data gathered will provide the necessary air flow information for Green Star to design, engineer, and optimize this 50 MW potential wind farm.

The Municipality of Veliko Gradiste is located in north-east Serbia approximately 100 km east of the capital, Belgrade. Its territory encompasses 344 square km on the right bank of the Danube River and left bank of the Pek River. The initial micro location for placement of the Company's wind sensor had been identified next to the settlement of Ram, and the Municipality has allotted 200 hectares of land towards this endeavour.

About Green Star Alternative Energy (GSAE.PK) Green Star Alternative Energy is an environmentally conscious, renewable energy company working to develop more than 300 MW (megawatts) of clean electricity through wind energy. The corporate revenue model is two-fold: the use of a renewable resource allows not only for the creation of environmentally friendly energy, but the granting of carbon (greenhouse gas) emission credits which may be traded and sold. Green Star is pursuing a significant opportunity to provide clean energy to the growing Republic of Serbia and neighbouring European countries. Through a joint venture with key wind farm and power trading company Notos, Green Star will become the nation's first developer of wind power. GSAE is focused on green technology and sustainable energy programs like wind turbines, hydro electric power generation, and other renewable electricity models.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: BCSI - Blue Coat Systems, Inc.)

LATEST NEWS!!

Blue Coat Expands Relationship With Microsoft to Advance Application Delivery Networking

Becomes Microsoft Gold Certified Partner for Advanced Infrastructure Optimization and ISV Solutions; Also Joins Protocol Optimization Licensing Program

SUNNYVALE, Calif., Nov 09, 2009 -- Blue Coat Systems, Inc. (Nasdaq:BCSI), the technology leader in Application Delivery Networking, today announced it has become a Microsoft Gold Certified Partner and joined the Microsoft Protocol Optimization Licensing Program (POLP). In addition, Blue Coat is a member of the Microsoft Communication Protocol Program.

The status of Gold Certified Partner represents the highest level of competence and expertise with Microsoft technologies, and provides the closest working relationship with Microsoft. Blue Coat has Microsoft Gold Certified Partner competencies in advanced infrastructure optimization and ISV software solutions. As a Microsoft Gold Certified Partner Blue Coat personnel receive unlimited technical support and training from Microsoft as well as a myriad of marketing benefits.

Participation in POLP enables Blue Coat to enhance the performance of Microsoft applications and protocols. Blue Coat solutions accelerate remote access to Microsoft Office or SharePoint files, Microsoft Exchange, Microsoft -SQL Server and other business-enabling applications. POLP provides WAN optimization vendors with access to key Microsoft technology and protocols to enable them to more effectively apply acceleration techniques to speed application performance across the Wide Area Network (WAN) to branch office-based employees or to remote employees outside of an office.

Blue Coat is the only WAN optimization vendor that is also a member of the Microsoft Communication Protocol Program (MCPP) and Blue Coat has specifically licensed the Windows Media Server protocol for proxy caching. Blue Coat ProxySG appliances deployed in branch offices can cache on-demand video locally to serve it more quickly and efficiently to users in remote offices. In addition, videos can be automatically pre-populated or pre-positioned for anticipated use in branch offices at a later time.

Blue Coat periodically conducts protocol interoperability tests at the Microsoft Enterprise Engineering Center (EEC) at Redmond, WA where Microsoft assists Blue Coat's R&D team to maintain ProxySG interoperability with CIFS/SMB, Media Server, Exchange (MAPI) and other MS Office protocol optimizations.

"As the technology leader of Application Delivery Networking, we value our relationship with Microsoft in our ongoing work to extend application visibility, acceleration and security solutions," said Bethany Mayer, senior vice president of worldwide marketing and corporate development, Blue Coat Systems. "Microsoft applications and technology play a critical role in any business, and Blue Coat is committed to enhancing their use and value across the extended enterprise." About Blue Coat Systems Blue Coat Systems is the technology leader in Application Delivery Networking. Blue Coat offers an Application Delivery Network Infrastructure that provides the visibility, acceleration and security required to optimize and secure the flow of information to any user, on any network, anywhere. This application intelligence enables enterprises to tightly align network investments with business requirements, speed decision making and secure business applications for long-term competitive advantage. For additional information, please visit www.bluecoat.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: BJRI - BJ's Restaurants, Inc.)

LATEST NEWS!!

BJ's Restaurants, Inc. to Attend the Stephens 2nd Annual Restaurant Investor Conference

HUNTINGTON BEACH, Calif., Nov 9, 2009 -- BJ's Restaurants, Inc. (Nasdaq:BJRI) will be attending the Stephen's 2nd Annual Restaurant Investor Conference at the Bellagio Hotel in Las Vegas, Nevada. The Company will be hosting a series of investor meetings at the conference on Thursday, November 12th.

BJ's Restaurants, Inc. currently owns and operates 91 casual dining restaurants under the BJ's Restaurant & Brewery, BJ's Restaurant & Brewhouse or BJ's Pizza & Grill brand names. BJ's restaurants offer an innovative and broad menu featuring award-winning, signature deep-dish pizza complemented with generously portioned salads, appetizers, sandwiches, soups, pastas, entrees and desserts. Quality, flavor, value, moderate prices and sincere service remain distinct attributes of the BJ's experience. The Company operates several microbreweries which produce and distribute BJ's critically acclaimed handcrafted beers throughout the chain. The Company's restaurants are located in California (49), Texas (15), Arizona (5), Colorado (3), Oregon (2), Nevada (3), Florida (5), Ohio (2), Oklahoma (2), Kentucky (1), Indiana (1), Louisiana (1) and Washington (2). The Company also has a licensing interest in a BJ's restaurant in Lahaina, Maui. Visit BJ's Restaurants, Inc. on the Web at http://www.bjsrestaurants.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ : BRKR - Bruker Corp.)

LATEST NEWS!!

Bruker Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer

BILLERICA, Mass., Nov 09, 2009 -- Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors has appointed Bill Knight to Chief Operating Officer (COO) and Brian Monahan to Chief Financial Officer (CFO), with an effective date of February 1st, 2010. Presently, Bill Knight is serving as CFO, and Brian Monahan is serving as Chief Accounting Officer of Bruker Corporation.

Frank Laukien, Bruker's President and CEO, stated: "Bruker has a 49 year proud history of technology leadership and customer-focused product innovation. Going forward, we believe that the combination of continued innovation and an increased focus on operational excellence will drive margin expansion, balance sheet metrics and cash flow for increasing shareholder value. In order to drive our operational excellence initiative, we have created the new position of Chief Operating Officer at Bruker Corporation." He continued: "Today, we are very pleased to announce the promotion of two extremely capable individuals to expanded responsibilities. Over the past five years, Bill Knight has demonstrated strong financial and operational leadership at Bruker, and in his newly-created COO role Bill will lead and fully focus on our operation excellence initiative. Brian Monahan has been a key leader and contributor in our finance organization over the past five years, and we believe he is an excellent choice to succeed Bill as our CFO." Biographies Mr. Knight joined Bruker Corporation as CFO and Treasurer in October 2004. At Bruker, Mr. Knight is also the President of the Bruker Detection business in the United States. Before joining the Company, Mr. Knight served as an operations-focused CFO in several public companies, and was a founder of ATI Technologies, an analytical instruments company, where he had both financial and operational responsibilities. Mr. Knight served as CFO of Anika Therapeutics, Inc., from 2002 to 2004. He served as CFO of Zycos, Inc., a developer of DNA-based therapeutic products, from 2000 to 2002, and as CFO of NMT Medical, Inc., a provider of cardiovascular and neurological medical devices, from 1998 to 2000. Mr. Knight is a Certified Public Accountant and holds a B.B.A. in Accounting from the University of Wisconsin.

Mr. Monahan joined Bruker Corporation as the Corporate Controller in April 2004 and was appointed Chief Accounting Officer and Vice President of Finance in March 2009. In addition to his corporate responsibilities, Mr. Monahan has served in both financial and operational roles in the Bruker Daltonics division, where he has been an Executive Vice President of Bruker Daltonics since November 2006 and General Manager of the Americas since July 2008. From January 2005 to November 2006, Mr. Monahan was Vice President of Finance for Bruker Daltonics, and from July 2004 to January 2005 he was Assistant Vice President of Finance for Bruker Daltonics. Before joining the Company, from 2002 through 2004, Mr. Monahan served as the Manager of Accounting and Financial Reporting at Fisher Scientific International, Inc., and as an audit manager for PricewaterhouseCoopers LLP from 1999 through 2002. Mr. Monahan is a Certified Public Accountant and holds a B.S. in Accounting from the University of Massachusetts.

ABOUT BRUKER CORPORATION Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation, please visit www.bruker.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CBST - Cubist Pharmaceuticals, Inc.)

LATEST NEWS!!

The Boston Globe names Cubist to Globe 100's Top Places to Work '09

Top-ranked life sciences company

LEXINGTON, Mass., Nov 09, 2009 -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has been named one of the Top Places to Work in Massachusetts in the second annual employee-based survey from The Boston Globe. The Globe 100's Top Places to Work '09 magazine was published in the Sunday Globe on November 8th. Online, the report can be found at www.boston.com/topworkplaces. Cubist was ranked 37th on the overall list and is the top-ranked life sciences company on the list. Cubist also appeared on last year's inaugural list.

Produced by the same team that compiles the 22-year-old Globe 100 report of the best-performing public companies in Massachusetts, where Cubist ranked number one earlier this year, the Top Places to Work recognizes the most progressive companies in the state based on employee opinions about company leadership, compensation and training, diversity/inclusion, career development, family-friendly flexibility, and values and ethics. Private companies and nonprofits as well as publicly-held businesses were included in the analysis.

The rankings in the Globe 100's Top Places to Work are based on survey information collected by Workplace Dynamics, an independent company specializing in employee engagement and retention, from 86,000 employees at 269 Massachusetts organizations. This marks the second year that a Globe 100 report has honored private as well as publicly-held organizations.

Cubist President and CEO Michael Bonney said, "This recognition from the Boston Globe reaffirms what all of us at Cubist feel every day -- this is a great place to work! Our employees are committed to building the world's leading company focused on providing therapies for acutely ill patients. To ensure that mission's success, we depend on retaining and attracting the best and most highly motivated and committed scientific and business talent. Creating a positive work environment helps us achieve that end." Steve Ainsley, the publisher of The Boston Globe, stated, "The companies included in the Globe 100's Top Places to Work have succeeded in creating a positive workplace for their employees in the midst of the uncertainties of the general economy. I congratulate each of them for an outstanding accomplishment." To qualify for the Globe 100's Top Places to Work, a company must have more than 100 employees in Massachusetts. Nearly 600 qualified companies accepted an invitation to participate. Rankings were based on composite scores calculated purely on the basis of employee responses.

About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM(R) I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and CONSERV(TM)-2 -- for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND program underway in novel treatments for respiratory syncytial virus (RSV) infections in children using Alnylam's RNA-interference (RNAi) technology. The RSV program also includes ALN-RSV01, for which Cubist has opt-in rights after Alnylam completes a Phase 2b study of ALN-RSV01 for the treatment of RSV infection in adult lung transplant patients. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CGEN - Compugen Ltd.)

LATEST NEWS!!

Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes

Biomarker Discovered Using Compugen's GeneVa(R) Platform

TEL AVIV, Israel, Nov 09, 2009 -- Compugen Ltd. (NASDAQ:CGEN) announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen's GeneVa(R) platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.

Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90% of whom are affected by type 2 diabetes. During the past few years, extensive efforts by others searching for genetic markers for type 2 diabetes have utilized numerous genome-wide association studies, involving thousands of patients globally. Several validated genetic markers have been found; however, combining all the discovered biomarkers still explains only a small fraction of the heritability of the disease, so the need for additional markers continues to exist.

From the approximately 350,000 multiple nucleotide genetic variations predicted by the GeneVa(R) platform, a very small set of variations was selected as being potentially related to type 2 diabetes in Caucasians. This very small set, consisting of only 135 variations, was then tested in a genotyping experiment. In this study, CGEN-40001, a novel 15bp insertion in PFKP (a key regulatory enzyme in glycolysis), demonstrated the predicted correlation with type 2 diabetes in Caucasians. This correlation was then validated in a second study based on an independent set of samples. According to the two studies performed by Compugen, approximately 15% of the Caucasian population has at least one copy of this insertion. Furthermore, the studies showed that the presence of this insertion increases the risk of type 2 diabetes by 50-80%.

About Type 2 Diabetes Diabetes mellitus type 2 is a chronic, life-long disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. When glucose builds up in the blood rather than being absorbed into cells, it can lead to diabetic complications. Over time, diabetes can lead to blindness, kidney failure and nerve damage. Diabetes is also an important factor in accelerating the hardening and narrowing of arteries (atherosclerosis), which generally leads to strokes, coronary heart disease and other large blood vessel diseases. If left uncontrolled, the consequences can be life-threatening. However, type 2 diabetes is manageable and can be prevented. "First-line" treatment consists of diet, weight control and physical activity.

At present, an estimated 8% of the U.S. population suffers from diabetes, 90% of whom are affected by type 2 diabetes. Moreover, prevalence rates in the U.S. have more than doubled since 1990, leading the U.S. Center for Disease Control to characterize this continuing increase as an epidemic. Worldwide, more than 150 million people are estimated to have this disorder; this number is expected to double by 2025.

About Compugen's GeneVa(R) Platform Compugen's GeneVa(R) platform incorporates an in silico database of approximately 350,000 predicted human genetic variations. Each of these predicted variations consists of multiple consecutive nucleotides (in general varying between 2 and 500 nucleotides) and can be in the form of insertions, deletions and/or copy-number variations in the genome. Thus, these GeneVa(R) variations are much larger than the more commonly known SNP's (Single Nucleotide Polymorphisms), millions of which are known to occur in the human genome, and with each SNP involving a change in only one nucleotide. It is generally believed that larger variations should have a more significant impact.

GeneVa(R) utilizes special purpose algorithms and other computational biology tools to select from the large database of genetic variations those variations that are predicted to be associated with the specific clinical phenotypes of interest, such as response or non-response to a specified drug of interest, or predisposition to a specified disease. Another key feature of the platform is a proprietary genotyping capability that allows the testing of multiple genetic variations on hundreds of DNA samples in a precise and cost-effective manner.

About Compugen Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's current collaborations include Bayer Schering Pharma, Biosite, Medarex, Inc., Merck & Co., Inc., Merck Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd. www.evogene.com (TASE: EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate Web site at www.cgen.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.